Preferences help
enabled [disable] Abstract
Number of results
2014 | 4 | 3 | A117-120
Article title

Everolimus – effectively reverses acquired resistance on endocrine therapy of patients with advanced breast cancer. A case report

Title variants
Languages of publication
Breast cancer is the most common malignancy among women in Poland. Endocrine therapy is the first line of treatment in hormone-receptor-positive advanced breast cancer. Progression during endocrine therapy is unavoidable. Administration of mTOR inhibitor gives a chance of reversing the acquired resistance. This paper presents a case report of a patient with metastatic breast cancer successfully treated with everolimus added to endocrine therapy.
Physical description
  • Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Krakow Branch
  • Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Krakow Branch
  • Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Krakow Branch
  • Krzakowski M., Fijuth J., Herman K. et al.: Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych. Tom I. Polska Unia Onkologii 2013.
  • Wojciechowska U., Didkowska J., Zatoński W.: Prognozy zachorowalności i umieralności na nowotwory złośliwe w Polsce do 2025 r. Krajowy Rejestr Nowotworów, Centrum Onkologii Instytutu im. M. Skłodowskiej-Curie.
  • Blamey R.W., Cataliotti L.: EUSOMA accreditation of breast units. Eur. J. Cancer 2006; 42: 13331-1337.
  • Wilcken N., Hornblucke J., Ghersi D.: Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst. Rev. 2003; (2): CD002747.
  • Wong M.H.F., Stockler M., Pavlakis N.: Bisphosphonates and other bone agents for breast cancer. Cochrane Library February 2012.
  • Van Poznak C.H., Temin S., Yee G.C. et al.: American society of clinical oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J. Clin. Oncol. 2011; 29(9): 1221-1227.
  • Cardoso F., Costa A., Norton L. et al.: 1st International consensus guidelines for advanced breast cancer (ABC 1). The Breast 2012; 21(3): 242-252.
  • Łacko A., Duchnowska R.: The place of exemestane in the treatment of advanced breast cancer in postmenopausal patients. Onkol. Prakt. Klin. 2012; 8(6): 246-251.
  • Wojtukiewicz M., Sierko E.: Leczenie ukierunkowane na cele molekularne w onkologii i hematoonkologii. Via Medica 2013.
  • Baselga J., Campone M., Piccart M. et al.: Everolimus in post-menopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 2012; 366: 520-529.
  • Amir E., Miller N., Geddie W. et al.: Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J. Clin. Oncol. 2012; 30: 587-592.
  • Simmonds C., Miller N.,Geddie W. et al.: Does confirmatory tumor biopsy alter the management of breast cancer with distant metastases? Ann. Oncol. 2009; 20: 1499-1504.
  • Cardoso F., Fallowfield L., Costa A. et al.; ESMO Guidelines Working Group: Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2011; 22(suppl. 6): 25-30
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.